Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Adaptive Biotechnologies stock

Learn how to easily invest in Adaptive Biotechnologies stock.

Adaptive Biotechnologies Corp is a biotechnology business based in the US. Adaptive Biotechnologies shares (ADPT) are listed on the NASDAQ and all prices are listed in US Dollars. Adaptive Biotechnologies employs 858 staff and has a trailing 12-month revenue of around $159.7 million.

How to buy shares in Adaptive Biotechnologies

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ADPT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Adaptive Biotechnologies stock price (NASDAQ: ADPT)

Use our graph to track the performance of ADPT stocks over time.

Adaptive Biotechnologies shares at a glance

Information last updated 2022-09-27.
Latest market close$7.12
52-week range$5.96 - $37.55
50-day moving average $9.57
200-day moving average $12.68
Wall St. target price$13.17
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.63

Buy Adaptive Biotechnologies shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$0
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Public
Stocks, ETFs, Cryptocurrency
$0
$0
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Tradier
Stocks, Options, ETFs
$0
$0
N/A
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Adaptive Biotechnologies stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Adaptive Biotechnologies price performance over time

Historical closes compared with the close of $7.12 from 2022-09-28

1 week (2022-09-22) 3.19%
1 month (2022-08-29) -26.52%
3 months (2022-06-29) -13.38%
6 months (2022-03-25) -44.11%
1 year (2021-09-29) -78.07%
2 years (2020-09-29) -85.18%
3 years (2019-09-27) 30.31
5 years (2017-09-25) N/A

Adaptive Biotechnologies financials

Revenue TTM $159.7 million
Gross profit TTM $91 million
Return on assets TTM -15.86%
Return on equity TTM -38.33%
Profit margin -145.37%
Book value $3.63
Market capitalisation $933 million

TTM: trailing 12 months

Adaptive Biotechnologies share dividends

We're not expecting Adaptive Biotechnologies to pay a dividend over the next 12 months.

Adaptive Biotechnologies share price volatility

Over the last 12 months, Adaptive Biotechnologies's shares have ranged in value from as little as $5.955 up to $37.55. A popular way to gauge a stock's volatility is its "beta".

ADPT.US volatility(beta: 0.95)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adaptive Biotechnologies's is 0.9532. This would suggest that Adaptive Biotechnologies's shares are less volatile than average (for this exchange).

Adaptive Biotechnologies overview

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test.

Frequently asked questions

What percentage of Adaptive Biotechnologies is owned by insiders or institutions?
Currently 1.648% of Adaptive Biotechnologies shares are held by insiders and 86.649% by institutions.
How many people work for Adaptive Biotechnologies?
Latest data suggests 858 work at Adaptive Biotechnologies.
When does the fiscal year end for Adaptive Biotechnologies?
Adaptive Biotechnologies's fiscal year ends in December.
Where is Adaptive Biotechnologies based?
Adaptive Biotechnologies's address is: 1165 Eastlake Avenue East, Seattle, WA, United States, 98109
What is Adaptive Biotechnologies's ISIN number?
Adaptive Biotechnologies's international securities identification number is: US00650F1093
What is Adaptive Biotechnologies's CUSIP number?
Adaptive Biotechnologies's Committee on Uniform Securities Identification Procedures number is: 00650F109

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site